An interventional study of AMADEO and Training in Parkinson Disease, sponsored by IRCCS Centro Neurolesi Bonino Pulejo. Recruiting at 1 site in Italy. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-03-19.
Sponsored by IRCCS Centro Neurolesi Bonino Pulejo · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Parkinson Disease by IRCCS Centro Neurolesi Bonino Pulejo — 6 open to participants now, 8 under way, none of them phase 3. Parkinson Disease · IRCCS Centro Neurolesi Bonino Pulejo.
Among the 13 studies in Parkinson Disease by IRCCS Centro Neurolesi Bonino Pulejo, this one is the 8th largest by planned enrollment, is one of 2 that started in 2019, is one of 13 with no phase, and was the 3rd registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →6 of the 13 studies in Parkinson Disease by IRCCS Centro Neurolesi Bonino Pulejo are open now, in 1 country. Recruiting first, the newest first:
IRCCS Centro Neurolesi Bonino Pulejo · Sites in Italy
Ages 40–70
IRCCS Centro Neurolesi Bonino Pulejo · Sites in Italy
Ages 18–75
IRCCS Centro Neurolesi Bonino Pulejo · Sites in Italy
Ages 40–80
IRCCS Centro Neurolesi Bonino Pulejo · Sites in Italy
Ages 18–70 · Healthy volunteers
IRCCS Centro Neurolesi Bonino Pulejo · Sites in Italy
Ages 18–90 · Healthy volunteers
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 45 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 2 started in 2019.
This study's planned enrollment of 40 is close to the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 60 across the 13 interventional studies. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
IRCCS Centro Neurolesi Bonino Pulejo is the lead sponsor of 67 studies on the registry; 30 are open to participants now.
2 of the studies in Parkinson Disease by IRCCS Centro Neurolesi Bonino Pulejo that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06838975IRCCS Centro Neurolesi Bonino PulejoVirtual Reality Rehabilitation for Cognitive, Emotional, and Motor Recovery in Neurological Disorders | 2027-09-29 |
| NCT07434089IRCCS Centro Neurolesi Bonino PulejoImpact of C-Mill Rehabilitation on the Gut-Brain Axis in Parkinson's Disease | 2027-10-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Parkinson Disease by IRCCS Centro Neurolesi Bonino Pulejo, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Hand movements are particularly impaired in Parkinson's Disease (PD) patients contributing to functional disability and difficulties in activities of daily living. AMADEO®. is an end-effector system enables intensive training with frequently repeated gripping movements. It offers the possibility to select from between passive, assistive and active modes using exercise of finger strength, finger movement, movement control and a selective activation of the fingers.Aim of this study is to evaluate the efficacy of the end-effector finger system, AMADEO®, on hand-finger movements in PD patients evaluating the improvement on finger tapping and agility of hand movement item scores on the MDS-UPDRS, variation on the active finger strengths and the active and passive Range of Motion (ROM); variation on Electromyographic (EMG)-parameters.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Twenty PD patients with hand bradykinesia will be treated with the AMADEO® system. They will undergo 15 training sessions, 5 a week for 3 weeks, each session lasting about 60 minutes. During each session, both the hands will be treated using the endeffector in its active and active-assisted modality.
Device: AMADEO · Other: Training
Twenty control subjects (PD patients) will be treated with traditional rehabilitation focused on fine hand-finger movement skills. The patients in this group will undergo the same amount of treatment. Both the groups will be trained with conventional physiotherapy concerning postural, balance and gait.
Other: OT Training
AMADEO® is an end-effector system enables intensive training with frequently repeated gripping movements. It offers the possibility to select from between passive, assistive and active modes using exercise of finger strength, finger movement, movement control and a selective activation of the fingers. Moreover, even without muscular strength, active work can be done using EMG-based training. The Continuous Passive Motion (CPM Plus) therapy facilitates the implementation of automatic movement sequences even when the patient is unable to complete the entire range of motion on their own. It may be used in all phases of finger-hand rehabilitation and can be adapted to the needs of every patient. In patients with PD, it will be useful in improving bradykinesia and potentially distal hypostenia.
training
training
Nine hole peg test
9HPT is used to measure finger dexterity in patients with various neurological diagnoses
Time frame: 1 month
Bipolar surface electromyography
EMG will be recorded from the first dorsal interossieous (FDI) and extensor digitorum communis (EDC) muscles.
Time frame: 1 month
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2019 to primary completion in Dec 2019, 3 months.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's 3 months is below that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRCCS Centro Neurolesi Bonino Pulejo